Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience

Haemophilia

Volumn 18, Issue 1, 2012, Pages

  Auerswald, G ^a   Bidlingmaier, C ^b   Kurnik, K ^b  

^a KLINIKUM BREMEN MITTE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIGEN PRESENTING CELL; CELL ACTIVATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ETHNICITY; FEVER; FOLLOW UP; GENE MUTATION; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; LETTER; LOW DRUG DOSE; PHYSICAL DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; T LYMPHOCYTE; UPREGULATION; VACCINATION;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; FOLLOW-UP STUDIES; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; TIME FACTORS;

EID: 84355162170     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02659.x     Document Type: Letter

References (7)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Recombinant factor VIII for the prevention of joint disease in children with severe hemophilia: prophylaxis compared with episodic treatment. N Engl J Med 2007; 357: 535-44.
2. Gringeri A, Lundin B, von Mackensen S et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
3. Mancuso ME, Graca L, Auerswald G et al. Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention. Haemophilia 2009; 15(Suppl 1): 8-14.
4. Gouw S.C., van den Berg H.M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-34.
5. Pfistershammer K, Stöckl J, Siekmann J et al. Recombinant FVIII and FVIII/VWF complex do not present danger signals for human dendritic cells. Thromb Haemost 2006; 96: 309-16.
6. Reipert BM, van Helden PM, Schwarz HP et al. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136: 12-25.
7. Kurnik K., Bidlingmaier C, Engl W. et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.